Seattle-based biotech firm Omeros says its pipeline treatment to rival Alexion's Soliris is set to enter phase 3 later this year. Alexion's Soliris (eculizumab) is a blockbuster, earning $2.5 billion ...
The European Commission has granted an orphan drug designation to Alexion Pharmaceuticals’ Soliris (eculizumab) to prevent graft rejection in organ transplants. The European Commission has granted an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback